|
G |
FGF10 |
fibroblast growth factor 10 |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF10 protein |
CTD |
PMID:14699094 |
|
NCBI chr16:28,695,465...28,779,953
Ensembl chr16:28,695,470...28,777,509
|
|
G |
FGF18 |
fibroblast growth factor 18 |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF18 protein |
CTD |
PMID:14699094 |
|
NCBI chr16:52,724,867...52,760,246
Ensembl chr16:52,725,356...52,759,791
|
|
G |
FGF2 |
fibroblast growth factor 2 |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein |
CTD |
PMID:14699094 |
|
NCBI chr 8:101,278,877...101,344,084
Ensembl chr 8:101,278,885...101,343,916
|
|
G |
MDK |
midkine |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to MDK protein |
CTD |
PMID:14699094 |
|
NCBI chr 2:16,130,787...16,133,791
Ensembl chr 2:16,130,788...16,133,510
|
|
G |
PTN |
pleiotrophin |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to PTN protein |
CTD |
PMID:14699094 |
|
NCBI chr18:12,219,708...12,309,045
Ensembl chr18:12,219,787...12,309,044
|
|
|
G |
FGF10 |
fibroblast growth factor 10 |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF10 protein |
CTD |
PMID:14699094 |
|
NCBI chr16:28,695,465...28,779,953
Ensembl chr16:28,695,470...28,777,509
|
|
G |
FGF18 |
fibroblast growth factor 18 |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF18 protein |
CTD |
PMID:14699094 |
|
NCBI chr16:52,724,867...52,760,246
Ensembl chr16:52,725,356...52,759,791
|
|
G |
FGF2 |
fibroblast growth factor 2 |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein |
CTD |
PMID:14699094 |
|
NCBI chr 8:101,278,877...101,344,084
Ensembl chr 8:101,278,885...101,343,916
|
|
G |
MDK |
midkine |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to MDK protein |
CTD |
PMID:14699094 |
|
NCBI chr 2:16,130,787...16,133,791
Ensembl chr 2:16,130,788...16,133,510
|
|
G |
PTN |
pleiotrophin |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to PTN protein |
CTD |
PMID:14699094 |
|
NCBI chr18:12,219,708...12,309,045
Ensembl chr18:12,219,787...12,309,044
|
|
|
G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
multiple interactions increases expression |
EXP |
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 mRNA] Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein |
CTD |
PMID:30270565 |
|
NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328
|
|
G |
IL18 |
interleukin 18 |
increases expression multiple interactions |
EXP |
Dextran Sulfate results in increased expression of IL18 mRNA [Dextran Sulfate co-treated with Zearalenone] results in increased expression of IL18 mRNA; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of IL18 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 mRNA] |
CTD |
PMID:30270565 |
|
NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
multiple interactions increases expression |
EXP |
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of IL1B mRNA; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of IL1B mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA] |
CTD |
PMID:30270565 |
|
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions increases expression |
EXP |
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 protein; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of NLRP3 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein] Dextran Sulfate results in increased expression of NLRP3 mRNA; Dextran Sulfate results in increased expression of NLRP3 protein |
CTD |
PMID:30270565 |
|
NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228
|
|
G |
PYCARD |
PYD and CARD domain containing |
multiple interactions increases expression |
EXP |
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD protein Dextran Sulfate results in increased expression of PYCARD mRNA; Dextran Sulfate results in increased expression of PYCARD protein |
CTD |
PMID:30270565 |
|
NCBI chr 3:17,305,921...17,307,521
Ensembl chr 3:17,306,099...17,307,786
|
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
[laminaran co-treated with fucoidan co-treated with Minerals] promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:21948611 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
PSP-I |
porcine seminal protein I |
multiple interactions |
EXP |
zinc chloride promotes the reaction [PSP-I protein binds to Heparin]; Zinc promotes the reaction [PSP-I protein binds to Heparin] |
CTD |
PMID:16819821 |
|
NCBI chr14:132,302,376...132,309,388
Ensembl chr14:132,302,352...132,308,106
|
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
EXP |
EGFR protein affects the chemical synthesis of and affects the localization of Hyaluronic Acid |
CTD |
PMID:21520325 |
|
NCBI chr 9:139,302,410...139,474,632
Ensembl chr 9:139,300,022...139,475,589
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
[Flavones co-treated with Lipopolysaccharides] results in increased phosphorylation of AKT1 protein |
CTD |
PMID:31669396 |
|
|
|
G |
ALB |
albumin |
decreases expression |
EXP |
Lipopolysaccharides results in decreased expression of ALB protein |
CTD |
PMID:19477247 |
|
NCBI chr 8:69,643,427...69,663,152
Ensembl chr 8:69,531,487...69,721,696
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
Lipopolysaccharides results in increased expression of BAX protein Flavones inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] |
CTD |
PMID:31669396 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
increases expression |
EXP |
Lipopolysaccharides results in increased expression of BCL2 mRNA |
CTD |
PMID:21645290 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP3 |
caspase 3 |
increases expression multiple interactions |
EXP |
Lipopolysaccharides results in increased expression of CASP3 protein 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein]; [deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein; Flavones inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein]; MAP1LC3B protein affects the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein] |
CTD |
PMID:31669396 PMID:32877744 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP6 |
caspase 6 |
decreases expression |
EXP |
Lipopolysaccharides results in decreased expression of CASP6 mRNA |
CTD |
PMID:21645290 |
|
NCBI chr 8:112,519,450...112,534,315
Ensembl chr 8:112,520,629...112,537,045
|
|
G |
CAT |
catalase |
decreases expression multiple interactions |
EXP |
Lipopolysaccharides results in decreased expression of CAT mRNA Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of CAT mRNA] |
CTD |
PMID:36549457 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
multiple interactions |
EXP |
[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA] |
CTD |
PMID:30708112 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CCL20 |
C-C motif chemokine ligand 20 |
multiple interactions |
EXP |
[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA] |
CTD |
PMID:30708112 |
|
NCBI chr15:129,172,743...129,176,069
|
|
G |
CFLAR |
CASP8 and FADD like apoptosis regulator |
decreases expression |
EXP |
Lipopolysaccharides results in decreased expression of CFLAR mRNA |
CTD |
PMID:21645290 |
|
NCBI chr15:104,780,744...104,835,631
Ensembl chr15:104,781,616...104,835,630
|
|
G |
CLDN1 |
claudin 1 |
decreases expression multiple interactions |
EXP |
Lipopolysaccharides results in decreased expression of CLDN1 mRNA; Lipopolysaccharides results in decreased expression of CLDN1 protein [deoxynivalenol co-treated with Lipopolysaccharides] results in decreased expression of CLDN1 mRNA; [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA] |
CTD |
PMID:22092031 PMID:32877744 PMID:37271275 |
|
NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
increases secretion multiple interactions increases expression |
EXP |
Lipopolysaccharides results in increased secretion of CXCL8 protein 3',4',5'-trimethoxyflavone analog inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; [deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA; Apigenin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL8 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]; Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL8 protein |
CTD |
PMID:15912099 PMID:26180592 PMID:27861533 PMID:30708112 |
|
NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
|
|
G |
DIABLO |
diablo IAP-binding mitochondrial protein |
decreases expression |
EXP |
Lipopolysaccharides results in decreased expression of DIABLO mRNA |
CTD |
PMID:21645290 |
|
NCBI chr14:30,498,885...30,519,846
Ensembl chr14:30,498,900...30,520,070
|
|
G |
GH1 |
growth hormone 1 |
multiple interactions |
EXP |
GH1 protein inhibits the reaction [Lipopolysaccharides results in decreased abundance of Glucose]; GH1 protein inhibits the reaction [Lipopolysaccharides results in decreased expression of INS protein]; GH1 protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Bilirubin]; GH1 protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Fatty Acids, Nonesterified]; GH1 protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Urea]; GH1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:9185964 |
|
NCBI chr12:15,064,965...15,066,698
Ensembl chr12:15,064,909...15,066,696
|
|
G |
GPX1 |
glutathione peroxidase 1 |
decreases expression |
EXP |
Lipopolysaccharides results in decreased expression of GPX1 mRNA |
CTD |
PMID:36549457 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GRHPR |
glyoxylate and hydroxypyruvate reductase |
affects expression |
EXP |
Lipopolysaccharides affects the expression of GRHPR mRNA |
CTD |
PMID:21645290 |
|
NCBI chr 1:238,139,764...238,151,631
Ensembl chr 1:238,139,794...238,152,382
|
|
G |
H2AX |
H2A.X variant histone |
increases expression multiple interactions |
EXP |
Lipopolysaccharides results in increased expression of H2AX protein Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of H2AX protein] |
CTD |
PMID:36549457 |
|
NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084
|
|
G |
HSPA14 |
heat shock protein family A (Hsp70) member 14 |
affects expression |
EXP |
Lipopolysaccharides affects the expression of HSPA14 mRNA |
CTD |
PMID:21645290 |
|
NCBI chr10:46,908,161...46,935,323
Ensembl chr10:46,904,311...46,935,280 Ensembl chr10:46,904,311...46,935,280
|
|
G |
IFNG |
interferon gamma |
increases expression |
EXP |
Lipopolysaccharides results in increased expression of IFNG mRNA |
CTD |
PMID:15998543 |
|
NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670
|
|
G |
IL10 |
interleukin 10 |
increases expression |
EXP |
Lipopolysaccharides results in increased expression of IL10 mRNA |
CTD |
PMID:15998543 |
|
NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378
|
|
G |
IL12A |
interleukin 12A |
increases expression |
EXP |
Lipopolysaccharides results in increased expression of IL12A mRNA |
CTD |
PMID:15998543 |
|
NCBI chr13:99,733,394...99,741,078
Ensembl chr13:99,733,394...99,741,078
|
|
G |
IL13 |
interleukin 13 |
increases expression |
EXP |
Lipopolysaccharides results in increased expression of IL13 mRNA |
CTD |
PMID:15998543 |
|
NCBI chr 2:134,972,099...134,976,672
Ensembl chr 2:134,972,623...134,975,093
|
|
G |
IL17A |
interleukin 17A |
multiple interactions |
EXP |
[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein; fumonisin B1 inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein]; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein] |
CTD |
PMID:30708112 |
|
NCBI chr 7:46,013,584...46,017,161
Ensembl chr 7:46,013,584...46,017,153
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions increases expression |
EXP |
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]] |
CTD |
PMID:28528741 |
|
NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119
|
|
G |
IL6 |
interleukin 6 |
increases secretion increases expression multiple interactions |
EXP |
Lipopolysaccharides results in increased secretion of IL6 protein Lipopolysaccharides results in increased expression of IL6 mRNA 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; Apigenin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; picolinic acid promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:8724211 PMID:26180592 PMID:27861533 PMID:32877744 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
INS |
insulin |
decreases expression multiple interactions |
EXP |
Lipopolysaccharides results in decreased expression of INS protein GH1 protein inhibits the reaction [Lipopolysaccharides results in decreased expression of INS protein] |
CTD |
PMID:9185964 |
|
NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
multiple interactions increases expression |
EXP |
[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:37271275 |
|
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions increases lipidation |
EXP |
deoxynivalenol inhibits the reaction [Lipopolysaccharides results in increased lipidation of MAP1LC3B protein]; MAP1LC3B protein affects the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of OCLN protein]]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TJP1 protein]]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] |
CTD |
PMID:32877744 |
|
NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
Lipopolysaccharides results in increased phosphorylation of MAPK1 protein ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:28528741 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK14 |
mitogen-activated protein kinase 14 |
multiple interactions increases expression |
EXP |
[SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA] |
CTD |
PMID:37271275 |
|
NCBI chr 7:31,791,398...31,861,544
Ensembl chr 7:31,790,877...31,862,031
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:28528741 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
MCL1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
EXP |
Lipopolysaccharides results in decreased expression of MCL1 mRNA |
CTD |
PMID:21645290 |
|
NCBI chr 4:98,562,092...98,567,014
Ensembl chr 4:98,534,812...98,567,006
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
increases expression multiple interactions |
EXP |
Lipopolysaccharides results in increased expression of MYD88 mRNA; Lipopolysaccharides results in increased expression of MYD88 protein ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 protein] |
CTD |
PMID:28528741 |
|
NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109
|
|
G |
NCF1 |
neutrophil cytosolic factor 1 |
decreases expression |
EXP |
Lipopolysaccharides results in decreased expression of NCF1 mRNA |
CTD |
PMID:21645290 |
|
NCBI chr 3:11,820,367...11,834,394
Ensembl chr 3:11,820,266...11,839,354
|
|
G |
NCF2 |
neutrophil cytosolic factor 2 |
decreases expression |
EXP |
Lipopolysaccharides results in decreased expression of NCF2 mRNA |
CTD |
PMID:21645290 |
|
NCBI chr 9:124,776,516...124,813,358
Ensembl chr 9:124,776,534...124,812,923
|
|
G |
NCF4 |
neutrophil cytosolic factor 4 |
decreases expression |
EXP |
Lipopolysaccharides results in decreased expression of NCF4 mRNA |
CTD |
PMID:21645290 |
|
NCBI chr 5:10,876,147...10,994,002
Ensembl chr 5:10,874,953...10,994,014
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions decreases expression |
EXP |
deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein] |
CTD |
PMID:32877744 |
|
NCBI chr 7:64,508,119...64,510,754
Ensembl chr 7:64,507,822...64,511,277
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions increases expression |
EXP |
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]]; [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA] Lipopolysaccharides results in increased expression of NLRP3 mRNA; Lipopolysaccharides results in increased expression of NLRP3 protein |
CTD |
PMID:32877744 PMID:37271275 |
|
NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228
|
|
G |
NOS2 |
nitric oxide synthase 2 |
affects expression |
EXP |
Lipopolysaccharides affects the expression of NOS2 mRNA; Lipopolysaccharides affects the expression of NOS2 protein |
CTD |
PMID:12893242 |
|
NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146
|
|
G |
OCLN |
occludin |
multiple interactions decreases expression |
EXP |
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of OCLN protein]]; [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of OCLN protein]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of OCLN protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA] Lipopolysaccharides results in decreased expression of OCLN mRNA; Lipopolysaccharides results in decreased expression of OCLN protein |
CTD |
PMID:32877744 PMID:37271275 |
|
NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP |
Lipopolysaccharides results in increased expression of PTGS2 mRNA 3',4',5'-trimethoxyflavone analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Apigenin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:26180592 PMID:27861533 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation multiple interactions |
EXP |
Lipopolysaccharides results in increased phosphorylation of RELA protein [deoxynivalenol co-treated with Lipopolysaccharides] affects the localization of RELA protein; [Flavones co-treated with Lipopolysaccharides] results in increased phosphorylation of RELA protein; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]; ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] |
CTD |
PMID:28528741 PMID:31669396 PMID:32877744 |
|
NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469
|
|
G |
ROCK1 |
Rho associated coiled-coil containing protein kinase 1 |
decreases expression |
EXP |
Lipopolysaccharides results in decreased expression of ROCK1 mRNA |
CTD |
PMID:21645290 |
|
NCBI chr 6:106,163,899...106,314,998
Ensembl chr 6:106,163,989...106,314,944
|
|
G |
SELE |
selectin E |
increases expression |
EXP |
Lipopolysaccharides results in increased expression of SELE |
CTD |
PMID:12224865 |
|
NCBI chr 4:81,289,061...81,299,657
|
|
G |
SIRPA |
signal regulatory protein alpha |
affects expression |
EXP |
Lipopolysaccharides affects the expression of SIRPA mRNA |
CTD |
PMID:21645290 |
|
NCBI chr17:33,566,270...33,611,375
|
|
G |
SIRT1 |
sirtuin 1 |
multiple interactions decreases expression |
EXP |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]]; Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein] |
CTD |
PMID:36549457 |
|
NCBI chr14:71,091,167...71,126,351
Ensembl chr14:71,091,167...71,123,297
|
|
G |
SLC38A1 |
solute carrier family 38 member 1 |
affects expression |
EXP |
Lipopolysaccharides affects the expression of SLC38A1 mRNA |
CTD |
PMID:21645290 |
|
NCBI chr 5:77,009,840...77,076,723
Ensembl chr 5:77,009,862...77,058,427
|
|
G |
SMARCA4 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
affects expression |
EXP |
Lipopolysaccharides affects the expression of SMARCA4 mRNA |
CTD |
PMID:21645290 |
|
NCBI chr 2:69,717,175...69,810,301
Ensembl chr 2:69,662,238...69,810,295
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP |
Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SOD1 mRNA] |
CTD |
PMID:36549457 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
decreases expression multiple interactions |
EXP |
Lipopolysaccharides results in decreased expression of TGFB1 mRNA 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TGFB1 mRNA]]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TGFB1 mRNA]; TGFB1 protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TGFB1 mRNA]] |
CTD |
PMID:32877744 |
|
NCBI chr 6:49,332,169...49,348,642
Ensembl chr 6:49,332,173...49,349,046
|
|
G |
TJP1 |
tight junction protein 1 |
decreases expression multiple interactions |
EXP |
Lipopolysaccharides results in decreased expression of TJP1 mRNA; Lipopolysaccharides results in decreased expression of TJP1 protein 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TJP1 protein]]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TJP1 mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TJP1 protein]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TJP1 protein]] |
CTD |
PMID:32877744 |
|
NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions increases expression |
EXP |
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] Lipopolysaccharides results in increased expression of TLR4 mRNA; Lipopolysaccharides results in increased expression of TLR4 protein |
CTD |
PMID:15998543 PMID:28528741 |
|
NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,058,970
|
|
G |
TNF |
tumor necrosis factor |
increases expression increases secretion multiple interactions |
EXP |
Lipopolysaccharides results in increased expression of TNF mRNA; Lipopolysaccharides results in increased expression of TNF protein Lipopolysaccharides results in increased secretion of TNF protein 3',4',5'-trimethoxyflavone analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF protein; [laminaran co-treated with fucoidan co-treated with Minerals] promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; GH1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; picolinic acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] |
CTD |
PMID:9185964 PMID:12406900 PMID:21948611 PMID:26180592 PMID:27861533 PMID:28528741 PMID:30708112 PMID:32877744 More...
|
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
IFNG |
interferon gamma |
increases expression |
EXP |
lipoteichoic acid results in increased expression of IFNG mRNA |
CTD |
PMID:15998543 |
|
NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670
|
|
G |
IL10 |
interleukin 10 |
increases expression |
EXP |
lipoteichoic acid results in increased expression of IL10 mRNA |
CTD |
PMID:15998543 |
|
NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378
|
|
G |
IL12A |
interleukin 12A |
increases expression |
EXP |
lipoteichoic acid results in increased expression of IL12A mRNA |
CTD |
PMID:15998543 |
|
NCBI chr13:99,733,394...99,741,078
Ensembl chr13:99,733,394...99,741,078
|
|
G |
IL13 |
interleukin 13 |
increases expression |
EXP |
lipoteichoic acid results in increased expression of IL13 mRNA |
CTD |
PMID:15998543 |
|
NCBI chr 2:134,972,099...134,976,672
Ensembl chr 2:134,972,623...134,975,093
|
|
G |
TLR4 |
toll like receptor 4 |
increases expression |
EXP |
lipoteichoic acid results in increased expression of TLR4 mRNA |
CTD |
PMID:15998543 |
|
NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,058,970
|
|